Skip to content
MARKETS / BALCAO / HCIL
BALCAO · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS · SMALL CAP

Hongchang International Co. Ltd. HCIL

15 fiscal years on record · USD · FY2024 reported · SEC filings only
$2.9M
▲ 7.1% YoY
$-472,393
$-11.4M
In brief

What this company does

As a holding company with no material operations of our own, we conduct our operations and operate our business in China through our subsidiaries. Holders of our stock hold equity interest in Hongchang International Co., Ltd, a Nevada holding company with business operations in China and therefore, may never hold equity interests directly in our Chinese operating entities. On August 21, 2023, the Company entered into a Share Exchange Agreement (the “Share Exchange Agreement”) with Hong Chang Global Investment Holdings Limited (“Hongchang BVI”) and Hongchang BVI’s stockholders, Zengqiang Investment Limited, a business company incorporated in the British Virgin Islands (“BVI”), and Hong Jin Investment Limited, a business company incorporated in the BVI (the “Selling Stockholders” and each a “Selling Stockholder”), in relation to the acquisition of Hongchang BVI by our Company (the “Hongchang Acquisition”).

Written from the business description in Hongchang International Co., Ltd's annual report to the U.S. Securities and Exchange Commission, filed 28 March 2025. Every sentence was checked against that document before publication.

Growth
USD 2.9M
Revenue, FY2024 · full 15-year series below
Revenue $M Net income $M
FY2024 · Revenue 2.9 · Net income -0.5
2.5M5.0M-2.0M20102012201420162018202020222024
Compound annual growth
+209.7%
+77.3%
−8.0%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +77.3% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−16 cents
lost on every revenue dollar
Operating margin Net margin
FY2024 · Operating -13.4% · Net -16.5%
-100%-200%-300%20102012201420162018202020222024
ROE
FY2023 · ROE -1.9%
-50%20102012201420162018202020222024

Cash & shareholders
returned in FY2024 · dividends + net buybacks
Free cash flow $M
FY2024 · FCF -11.4
-20M20102012201420162018202020222024

Total assetsUSD 57.5M
EquityUSD 38.8M
CashUSD 240,598.00
Gross debtUSD 6.8M
Net debtUSD 6.6M
Current ratio1.21×

Net debt stands at 17% of equity.

The 15-year record
15 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202420232022202120202019201820172016201520142013201220112010
Revenue $B0.00.00.00.00.00.0··0.00.00.00.00.00.0·
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.00.0
EBITDA $B−0.0−0.0−0.0······−0.0···−0.00.0
Income tax $B−0.0−0.0·········−0.00.0−0.00.0
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.00.0
Free cash flow $B−0.0−0.0········−0.0−0.0−0.0−0.0·
EPS, diluted $0.000.000.000.00·0.000.000.000.00−0.07−0.01−0.07−0.02−0.020.00
Dividend / sh $···············
Payout %···············
ROE %·−1.9·······−95.7−12.6−61.0−9.8−10.90.5
Shares out B0.520.520.421.030.001.031.140.030.050.050.050.050.050.050.05

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 60 reconciliationsAUDITED

Reconciled in 15 of 19 fiscal years. 35 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityElectromedical & Electrotherapeutic Apparatus
Listed onOTC market
Incorporated inNevada
Fiscal year endsMarch 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image